AI in Pharmaceuticals: Unveiling the Intelligent Solution

1. AI in Pharmaceuticals: Unveiling the Intelligent Solution GrapheneAI, a leader in advanced analytics based in Singapore, has made significant strides in pharmaceutical intelligence, leveraging AI in pharmaceuticals to address unique industry challenges. With operations in key markets including the USA, Japan, India, and Singapore, Graphene focuses exclusively on healthcare, bolstered by a team of experienced leaders and advisors with impressive academic and professional credentials. The company’sflagship solutionis designed to transform pharmaceutical intelligence through deep, data-driven insights into patient and doctor conversations, treatment trends, and therapeutic developments. AI in Pharmaceuticals: Why GrapheneAI? The pharmaceutical industry has long faced limitations with traditional AI applications, particularly due to generic AI’s reliance on limited medical datasets and focus on general social media chatter. The solution addresses these limitations by providing a pharma-specific AI solution that taps into over 500 curated databases, covering a wide range of sources, including regulatory journals, forums, and clinical research publications. Built by industry experts with profound domain knowledge, it offers actionable insights tailored specifically to the needs of the pharmaceutical industry, setting it apart from generic ‘AI in pharmaceuticals’ solutions. We have10+ years of experiencewith AI, and 7 out of the top 10 global pharma companies are our clients. AI in Pharmaceuticals: Key Features with Access to Extensive & Curated Databases

2. The solution uses a robust database comprising over 500 sources, ensuring that the AI system is informed by reliable, evidence-based data. Unlike generic AI, which may draw on non-specialized or public data, leverages a specialized database that includes regulatory records, clinical studies, blogs, and patient forums, ensuring that its analytics are highly relevant to the pharmaceutical sector. 1. Intelligent Listening and Customized Insights It does not just analyze data; it interprets and contextualizes information to deliver insights that can drive actionable decisions. For example, it can identify emerging trends in patient concerns, such as through analysis of chronic obstructive pulmonary disease (COPD) conversations on public forums. It also provides a competitive advantage by tracking brand perception across various channels, helping companies like GlaxoSmithKline (GSK) monitor and optimize their market strategies. 2. Reduced Costs and Minimized Human Error Automating data collection, filtering, and analysis significantly reduces the time and resources required for in-depth market research. Our AI-powered solution mitigates the risk of human error, which is particularly crucial in healthcare, where accurate data interpretation is essential. This efficiency also allows pharmaceutical companies to focus on strategic planning and decision-making rather than data processing. 3. Workflow Integration It seamlessly integrates with existing workflows, augmenting the resources that companies are already using. It builds on current data subscriptions and adds its own sources, enhancing the breadth of information available. This adaptability makes it easier for organizations to adopt without extensive overhauls of their current systems. AI in Pharmaceuticals: Real-World Applications and Case Studies 1. A Study Enhancing COPD Treatment Insights One of the primary demonstrations of its capabilities lies in its analysis of the study on COPD, a research effort involving over 10,000 patients. The study highlighted how a once- daily triple therapy, A, could significantly reduce exacerbations in COPD patients. It analyzed data on physician reactions to this study and found that COPD specialists were particularly optimistic, noting improvements in patient quality of life as a strong motivator for adopting the therapy. However, some physicians were hesitant, preferring a “wait-and-see” approach due to limited familiarity with the data. It identified this as an opportunity for educational efforts aimed at raising awareness and increasing physician confidence. This analysis not only provided insights into potential market acceptance but also identified key educational gaps that could impact the therapy’s adoption. Also, read about thepre-launch AI market analysis of our client’s COPD drug. 2. A Study Redefining Asthma Management Our study explored the effectiveness of an asthma treatment in real-world settings. The results demonstrated significant improvements in asthma control for patients using a specific medication combination, with 71% of patients showing better control compared to only 56% with usual care. The analysis indicated that healthcare providers responded positively, seeing the potential to change their approach to asthma management.

3. Some physicians, however, remained cautious, citing uncertainty about whether the study results applied universally. The insights revealed that these undecided doctors were often those who had not fully reviewed the findings, highlighting the need for targeted communication and further evidence dissemination to encourage broader adoption. 3. X/Y Differentiation: Tailored Insights for Prescribing Practices X and Y are both popular choices for treating COPD, but their applications vary significantly among physicians. GrapheneAI analyzed prescribing practices and found that general practitioners often used Y/Z combinations, while specialists leaned toward X/Y. This nuanced understanding helps pharmaceutical companies shape their engagement strategies by focusing on the preferences and decision-making processes of different healthcare provider segments. AI in Pharmaceuticals: Customizable Insights and Strategic Impact It offers several customizable outputs, allowing pharmaceutical companies to tailor its insights to meet specific needs:  Competitive Insights: It tracks perceptions of competitor brands across multiple platforms, providing a snapshot of brand influence and identifying potential areas of improvement. Event Analysis:Analyzing events that generate significant engagement (up to 330,000 views in certain cases) helps companies understand the impact of major announcements or product launches.   Social Media Monitoring: Its intelligent listening capabilities goes much beyond real- time monitoring of social media and listening, providing insights into public sentiment and brand perception. Our Edge with AI in Pharmaceuticals What makes GrapheneAI distinct is the singular focus on healthcare and pharmaceutical applications, a field where data specificity and accuracy are paramount. Generic “AI in pharmaceuticals” solutions lack the deep, specialized data it employs, resulting in insights that may not fully capture the complexities of healthcare trends. Our emphasis on reliable, actionable insights tailored to pharmaceutical needs allows companies to make data-driven decisions that are both evidence-based and strategically relevant. Furthermore, the leadership team at GrapheneAI, composed of experts, brings a wealth of knowledge in data science and healthcare, further validating the company’s commitment to pharmaceutical intelligence. AI in Pharmaceuticals: Final Thoughts Our solution is redefining what is possible with AI in the pharmaceutical industry. Through its targeted database, intelligent analytics, and customizable outputs, it empowers pharmaceutical companies to make informed, data-driven decisions that can shape patient care, product development, and market strategies. Contact usat GrapheneAI to set new standards for AI in pharmaceuticals because our tool stands as a groundbreaking solution as the demand for precise and reliable healthcare data grows.